for people ages 18 years and up (full criteria)
study started
estimated completion



This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Official Title

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma


Lymphoma, T-Cell Lymphoma, T-Cell, Cutaneous Mycosis Fungoides/Sezary Syndrome Mycoses Lymphoma Mycosis Fungoides Sezary Syndrome IPH4102


You can join if…

Open to people ages 18 years and up

Cohort 1:

  1. Relapsed and/or refractory stage IVA, IVB SS who have received at least two prior systemic therapies;
  2. Prior treatment with mogamulizumab;
  3. Patients should have blood stage B2 at screening based on central evaluation by flow cytometry;
  4. Feasibility of obtaining at least one skin biopsy at screening;

Cohorts 2 and 3:

  1. Relapsed and/or refractory stage IB, IIA, IIB, III, IV MF;
  2. KIR3DL2 expression (Cohort 2) or non-expression (Cohort 3) in at least one skin lesion based on central evaluation by IHC;
  3. Patients should have received at least two prior systemic therapies;
  4. Feasibility of obtaining at least one skin biopsy at screening;

Additional inclusion criteria applicable to all cohorts:

  1. Male or Female, at least 18 years of age;
  2. . ECOG performance status ≤2;
  3. . The patient must have a minimum wash-out period of 3 weeks between the last dose of prior systemic therapy and the first dose of IPH4102, except for mogamulizumab, a wash-out period of at least 8 weeks is required;
  4. . Patients should have recovered from all non-hematological adverse events related to prior therapy to ≤ grade 1 except for alopecia;
  5. . Adequate baseline laboratory data:


  • Hemoglobin >9 g/dL,
  • Absolute neutrophil count (ANC) ≥1,500/µL,
  • Platelets ≥100,000/µL,


  • Bilirubin ≤1.5 X upper limit of normal (ULN) or ≤3 X ULN for patients with Gilbert's disease,
  • Serum creatinine ≤1.5 X ULN,
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤2.5 X ULN.
  • . Women of childbearing potential (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12 months and capable to become pregnant. They must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment;
  • . Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug. Adequate methods are described in Appendix 11;
  • . Signed informed consent form prior to any protocol-specific procedures.

You CAN'T join if...

  1. Patients with evidence of large cell transformation (LCT) based on central histologic evaluation at screening;
  2. Concomitant corticosteroid use, systemic or topical. However, stable dosage of topical steroids (maximum strength Class III according to World Health Organization (WHO) Classification of Topical Corticosteroids) and/or systemic steroids (≤10 mg prednisone equivalent/day) are allowed, if patient has been on a stable dose for at least 4 weeks prior to treatment start. Inhaled steroids are allowed provided the presence of a concomitant medical condition that justifies the use;
  3. Receipt of live vaccines within 4 weeks prior the treatment;
  4. Central nervous system (CNS) lymphoma involvement;
  5. Prior administration of IPH4102;
  6. Concurrent enrollment in another clinical trial, unless it is an observational (non -interventional) clinical study or the follow-up period of an interventional study.
  7. Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents, extracorporeal photopheresis (ECP) or immunotherapy;
  8. Autologous stem cell transplantation less than 3 months prior to enrollment;
  9. Prior allogenic transplantation;
  10. . Patients who have undergone major surgery ≤ 4 weeks prior to study entry;
  11. . Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection;
  12. . Patients who have active Hepatitis B or C virus infection;
  13. . Known or tested positive for human immunodeficiency virus (HIV);
  14. . Patients with a history of other malignancies during the past five years apart from the disease subject of this study. The following are exempt from the five-year limit: non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia, Ductal carcinoma in situ (DCIS) or cervical carcinoma in situ;
  15. . Pregnant or breastfeeding women;
  16. . Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria;
  17. . Patients with autoimmune disease on systemic immunosuppressive treatment;
  18. . Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol;
  19. . Patients with dementia or altered mental status that would preclude understanding and rendering of informed consent document.


  • University of California, Los Angeles (UCLA) - Medical Center accepting new patients
    Los Angeles California 90095 United States
  • Stanford Cancer Center accepting new patients
    Stanford California 94305 United States


accepting new patients
Start Date
Completion Date
Innate Pharma
Phase 2
Study Type
Last Updated